AstraZeneca Price Target, Predictions & Analyst Ratings

GBX 8,321
-19.00 (-0.23 %)
(As of 06/14/2021 03:09 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume781,902 shs
Average Volume2.32 million shs
Market Capitalization£109.24 billion
P/E Ratio38.88
Dividend Yield2.48%

AstraZeneca (LON:AZN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
17 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is GBX 8,844.67 The high price target for AZN is £102 and the low price target for AZN is GBX 6,800. There are currently 4 sell ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
AZN Consensus Rating: BuyBuyBuyHold
AZN Consensus Rating Score: 2.532.562.502.35
AZN Analyst Ratings: 4 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
0 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
AZN Consensus Price Target: GBX 8,844.67GBX 8,886.25GBX 8,674.71GBX 8,515.29

AstraZeneca (LON:AZN) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca (LON:AZN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
6/8/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy£102
6/8/2021Credit Suisse GroupSet Price TargetBuyGBX 9,000
6/7/2021Liberum CapitalReiterated RatingBuyGBX 9,220
6/7/2021UBS GroupSet Price TargetBuyGBX 8,000
6/4/2021The Goldman Sachs GroupSet Price TargetSellGBX 6,800
6/4/2021Jefferies Financial GroupSet Price TargetBuyGBX 8,850
6/3/2021Kepler Capital MarketsSet Price TargetBuyGBX 9,000
5/11/2021Berenberg BankReiterated RatingBuyGBX 9,500
5/7/2021Shore CapitalReiterated RatingBuy
5/4/2021BarclaysReiterated RatingOverweight
5/3/2021DZ BankReiterated RatingSell
4/8/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy£100
12/7/2020Morgan StanleySet Price TargetBuyGBX 9,900
12/4/2020JPMorgan Chase & Co.Set Price TargetBuyGBX 9,500
6/22/2020Oddo BhfSet Price TargetSellGBX 7,600
6/22/2020Oddo SecuritiesDowngradeReduceGBX 8,100 ➝ GBX 7,600
6/2/2020Bryan, Garnier & CoBoost Price TargetBuyGBX 8,780 ➝ GBX 9,100
4/30/2020HSBCBoost Price TargetReduceGBX 6,450 ➝ GBX 6,690
4/15/2020Main First BankBoost Price TargetBuyGBX 8,100 ➝ GBX 8,800
10/8/2019Bank of AmericaReiterated RatingBuyGBX 8,500
9/10/2019Societe GeneraleReiterated RatingBuy
11/19/2018InvestecDowngradeHoldGBX 5,500 ➝ GBX 6,300
11/9/2018CfraSet Price TargetNeutralGBX 6,200
9/11/2018BNP ParibasSet Price TargetBuyGBX 6,500
(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.